DUBLIN, June 7, 2017 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announcedthat on June 7, 2017, the Hon. Joseph R. Goodwin, U.S. District Court Judge for the Southern District of West Virginia, entered a case management order in MDL 2325, American Medical Systems, Inc. Pelvic Repair System Products Liability Litigation (the "MDL") that includes a provision requiring plaintiffs in newly filed MDL cases to provide expert disclosures on specific causation within one hundred twenty (120) days of filing a claim (the "Order"). Under the Order, a plaintiff's failure to meet the foregoing deadline may be grounds for the entry of judgment against such plaintiff.
"We are very pleased with the entry of the Order by Judge Goodwin and we appreciate the cooperation of the leading MDL plaintiffs' counsel to achieve this result. We believe the entry of the Order constitutes significant progress toward reducing the number of newly filed MDL claims and ultimately resolving the litigation,"said Matthew J. Maletta, Endo's Executive Vice President, Chief Legal Officer. "We look forward to continuing to execute on our legal strategy, and more importantly, to serving our customers and the patients who rely on Endo's products."
About Endo International plc
Endo International plc(NASDAQ: ENDP) is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization.Endohas global headquarters inDublin, Ireland, and U.S. headquarters inMalvern, PA.Learn more atwww.endo.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements," including, but not limited to, the statements by Mr. Maletta, as well asEndo'sexpected, estimated or anticipated future results. Because forecasts are inherently estimates that cannot be made with precision,Endo'sperformance at times differs materially from its estimates and targets, andEndooften does not know what the actual results will be until after the end of the applicable reporting period. Therefore,Endowill not report or comment on its progress during a current quarter except through public announcement. Any statement made by others with respect to progress during a current quarter cannot be attributed to Endo. All forward-looking statements in this press release reflectEndo'scurrent analysis of existing trends and information and representEndo'sjudgment only as of the date of this press release. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially fromEndo'sexpectations and projections. Risks and uncertainties include, among other things, general industry and market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes, including regulatory decisions, product recalls, withdrawals and other unusual items; challenges related to product marketing, such as the unpredictability of market acceptance for new products and/or the acceptance of new indications for such products; inconsistency of treatment results among patients; potential difficulties in manufacturing; the outcome of litigation, settlement discussions or other adverse proceedings; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations. Endo expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Additional information concerning these and other risk factors can be found in Endo's periodic reports filed with the U.S. Securities and Exchange Commission and in Canada on the System for Electronic Data Analysis and Retrieval ("SEDAR"), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K.